LIPID FORMULATIONS FOR SPONTANEOUS DRUG ENCAPSULATION

摘要

A pharmaceutical formulation for pulmonary administration is disclosed. The pharmaceutical formulation comprises a lipid component and an active agent, wherein the pharmaceutical formulation has a liquid phase transition temperature of less than or equal to 37°C when hydrated and a liquid phase transition temperature of greater than 57°C when non-hydrated, whereby the lipid component spontaneously encapsulates and/or entraps the active agent when the pharmaceutical formulation is administered to the lungs. A targeting agent may also be provided. In one version, the pharmaceutical formulation is useful to treat an infection, such as an inhalation anthrax infection.